# A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

> **NCT07029711** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 225 (estimated)

## Conditions studied

- Severe Alopecia Areata

## Interventions

- **DRUG:** Ritlecitinib higher dose
- **DRUG:** Ritlecitinib lower dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07029711
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2027-04-20
- **Final completion:** 2027-05-18
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029711, "A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07029711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*